Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2021

July 2021 | 86 pages | ID: M96E0B03E45EEN
Global Markets Direct

Abstracts

Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2021

SUMMARY

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 11 molecules.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 2, 1 and 5 respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Central Nervous System, Genetic Disorders, Infectious Disease, Ophthalmology, Cardiovascular, Musculoskeletal Disorders, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Porphyria (Erythropoietic Protoporphyri), Rheumatoid Arthritis, Uveitis, Vitiligo, Acne Vulgaris, Acute Ischemic Stroke, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Pulmonary Fibrosis, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma) and Ulcerative Colitis.

The latest report Melanocyte Stimulating Hormone Receptor - Drugs In Development, 2021, outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
• The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Mitsubishi Tanabe Pharma Corp
Palatin Technologies Inc
SynAct Pharma AB
Viewpoint Molecular Targeting LLC
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dersimelagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8331 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Jul 07, 2021: SynAct Pharma announces additional data from the phase 2a trial of AP1189 in covid-19 infected patients and reminds of management call to discuss results
Jul 02, 2021: SynAct Pharma hosts conference call on positive data from a phase 2a trial of AP1189 in Covid-19 infected patients
Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis
Jun 30, 2021: SynAct Pharma announces positive data from a phase 2a trial of AP1189 in covid-19 infected patients
Jun 29, 2021: Palatin announces positive end-of-phase 2 meeting with FDA on PL9643 for the treatment of dry eye disease
Jun 23, 2021: SynAct Pharma files patent applications related to AP1189 derived APIs and oral formulations
Jun 07, 2021: First stroke patient treated with afamelanotide
Jun 01, 2021: SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
May 14, 2021: Palatin hosting key opinion leader webinar in role of melanocortin agonists in inflammation and the treatment of ocular indications
May 14, 2021: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.
May 04, 2021: SynAct Pharma expands AP1189 BEGIN study in rheumatoid arthritis UK version
May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting
Apr 20, 2021: Palatin announces two presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Apr 13, 2021: SynAct strengthens IP portfolio - Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version
Mar 31, 2021: Phase-2 clinical trial of MT-7117 initiated in the U.S., Canada, and Europe for the rare disease, diffuse cutaneous systemic sclerosis (dcSSc)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Clinuvel Pharmaceuticals Ltd, 2021
Pipeline by Eton Pharmaceuticals Inc, 2021
Pipeline by Mallinckrodt Plc, 2021
Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Pipeline by Palatin Technologies Inc, 2021
Pipeline by SynAct Pharma AB, 2021
Pipeline by Viewpoint Molecular Targeting LLC, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021